{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010525","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.844232+00:00","generated_at":"2026-05-21T04:58:18.911928+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June","bullets":["Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.","Cash balance $7.7M; expects to fund operations through merger close in June 2025.","Merger with Cullgen anticipated to close in June 2025; registration declared effective by SEC.","Company intends to divest assets including PUR3100 (Phase 2-ready acute migraine candidate) and iSPERSE technology.","R&D expenses decreased to less than $0.1M from $3.5M YoY due to wind-down."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010525","json":"https://secwatch.observer/filing/0001641172-25-010525.json","markdown":"https://secwatch.observer/filing/0001641172-25-010525.md","text":"https://secwatch.observer/filing/0001641172-25-010525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000164117225010525/0001641172-25-010525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000164117225010525/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:58:18.911928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}